Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult

Current Opinion in Hematology

Volumn 25, Issue 1, 2018, Pages 37-43

  Loftus, Tyler J ^a   Mohr, Alicia M ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

emergency myelopoiesis; myeloid derived suppressor cell; sepsis; stress erythropoiesis; trauma

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN RECEPTOR; HEPCIDIN;

ADAPTIVE IMMUNITY; ANEMIA; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; ERYTHROPOIESIS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOSPITAL INFECTION; HUMAN; LYMPHOCYTOPENIA; MYELOID-DERIVED SUPPRESSOR CELL; MYELOPOIESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UPREGULATION; ANIMAL; CYTOLOGY; LYMPHOCYTE; METABOLISM;

ANIMALS; HEMATOPOIESIS; HUMANS; LYMPHOCYTES; MYELOPOIESIS;

EID: 85036496477     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000395     Document Type: Review

References (110)

1. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1()CD11b() population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204:1463-1474.
2. Scumpia PO, Kelly-Scumpia KM, Delano MJ, et al. Cutting edge: bacterial infection induces hematopoietic stem and progenitor cell expansion in the absence of TLR signaling. J Immunol 2010; 184:2247-2251.
3. Kelly-Scumpia KM, Scumpia PO, Delano MJ, et al. Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10. J Exp Med 2010; 207:319-326.
4. Mohr AM, Upperman JS, Taneja R, et al. Differential effects of acute hypoxia and endotoxin on the secretion and expression of bone marrow interleukin-1 and interleukin-6. Shock 1997; 7:324-331.
5. Livingston DH, Wang MT, Hsieh J, et al. Hemorrhagic shock inhibits lipopolysaccharide-induced myelopoiesis in both germ-free and conventional rats. Surgery 1992; 112:773-779.
6. Cheshier SH, Prohaska SS, Weissman IL. The effect of bleeding on hematopoietic stem cell cycling and self-renewal. Stem Cells Dev 2007; 16:707-717.
7. Raff G, Livingston DH, Wang MT, Rameshwar P. Hemorrhagic shock abolishes the myelopoietic response to turpentine-induced soft tissue injury. J Surg Res 1995; 59:75-79.
8. Cohen MJ, Shankar R, Stevenson J, et al. Bone marrow norepinephrine mediates development of functionally different macrophages after thermal injury and sepsis. Ann Surg 2004; 240:132-141.
9. Tang Y, Shankar R, Gamboa M, et al. Norepinephrine modulates myelopoiesis after experimental thermal injury with sepsis. Ann Surg 2001; 233:266-275.
10. Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci USA 1997; 94:1908-1913.
11. Vignjevic S, Budec M, Markovic D, et al. Chronic psychological stress activates BMP4-dependent extramedullary erythropoiesis. J Cell Mol Med 2014; 18:91-103.
12. Nacionales DC, Szpila B, Ungaro R, et al. A detailed characterization of the dysfunctional immunity and abnormal myelopoiesis induced by severe shock and trauma in the aged. J Immunol 2015; 195:2396-2407.
13. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-174.
14. Bronte V. Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol 2009; 39:2670-2672.
15. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-4506.
16. Rodrigues JC, Gonzalez GC, Zhang L, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010; 12:351-365.
17. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546-2553.
18. Heim CE, Vidlak D, Kielian T. Interleukin-10 production by myeloid-derived suppressor cells contributes to bacterial persistence during Staphylococcus aureus orthopedic biofilm infection. J Leukoc Biol 2015; 98:1003-1013.
19. Zhao X, Rong L, Zhao X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 2012; 122:4094-4104.
20. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010; 40:2969-2975.
21. Darcy CJ, Minigo G, Piera KA, et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care 2014; 18:R163.
22. Janols H, Bergenfelz C, Allaoui R, et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in Gram-positive cases. J Leukoc Biol 2014; 96:685-693.
23. Mathias B, Delmas AL, Ozrazgat-Baslanti T, et al. Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock. Ann Surg 2017; 265:827-834.
24. Cuenca AG, Delano MJ, Kelly-Scumpia KM, et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 2011; 17:281-292.
25. Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32:790-802.
26. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109:625-637.
27. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111:219-228.
28. Panka DJ, Liu Q, Geissler AK, Mier JW. Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b/Gr-1 myeloid derived suppressor cells. Mol Cancer 2013; 12:17.
29. Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1CD11b myeloid cells that promote metastasis. Cancer Cell 2008; 13:23-35.
30. Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumorinfiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013; 73:2782-2794.
31. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014; 74:5057-5069.
32. Ueda Y, Cain DW, Kuraoka M, et al. IL-1R type I-dependent hemopoietic stem cell proliferation is necessary for inflammatory granulopoiesis and reactive neutrophilia. J Immunol 2009; 182:6477-6484.
33. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 2005; 201: 1771-1780.
34. Tebartz C, Horst SA, Sparwasser T, et al. A major role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immunosuppression during Staphylococcus aureus infection. J Immunol 2015; 194:1100-1111.
35. Kusmartsev S, Cheng F, Yu B, et al. All-Trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63:4441-4449.
36. Fricke I, Mirza N, Dupont J, et al. Vascular endothelial growth factor-Trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007; 13: 4840-4848.
37. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150-4166.
38. Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci USA 2011; 108: 17111-17116.
39. Monaghan SF, Thakkar RK, Tran ML, et al. Programmed death 1 expression as a marker for immune and physiological dysfunction in the critically ill surgical patient. Shock 2012; 38:117-122.
40. Huang X, Venet F, Wang YL, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U A 2009; 106:6303-6308.
41. Zhang Y, Li J, Lou J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care 2011; 15:R70.
42. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69: 2514-2522.
43. Guignant C, Lepape A, Huang X, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011; 15:R99.
44. Brahmamdam P, Inoue S, Unsinger J, et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010; 88:233-240.
45. Young WA, Fallon EA, Heffernan DS, et al. Improved survival after induction of sepsis by cecal slurry in PD-1 knockout murine neonates. Surgery 2017; 161:1387-1393.
46. Shindo Y, McDonough JS, Chang KC, et al. Anti-PD-L1 peptide improves survival in sepsis. J Surg Res 2017; 208:33-39.
47. Patera AC, Drewry AM, Chang K, et al. Frontline science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol 2016; 100:1239-1254.
48. Gregoire M, Tadie JM, Uhel F, et al. Frontline science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. J Leukoc Biol 2017; 101:1281-1287.
49. Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 2000; 13:110-116.
50. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4 T lymphocytes in humans. J Immunol 2001; 166:6952-6963.
51. Le Tulzo Y, Pangault C, Gacouin A, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002; 18:487-494.
52. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306:2594-2605.
53. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15:486-499.
54. Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology 2015; 479-480:180-193.
55. Tinoco R, Alcalde V, Yang Y, et al. Cell-intrinsic transforming growth factorbeta signaling mediates virus-specific CD8 T cell deletion and viral persistence in vivo. Immunity 2009; 31:145-157.
56. Garidou L, Heydari S, Gossa S, McGavern DB. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection. J Virol 2012; 86:7060-7071.
57. Boettler T, Cheng Y, Ehrhardt K, von Herrath M. TGF-beta blockade does not improve control of an established persistent viral infection. Viral Immunol 2012; 25:232-238.
58. Vezys V, Penaloza-MacMaster P, Barber DL, et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol 2011; 187:1634-1642.
59. Liu QY, Yao YM, Yu Y, et al. Astragalus polysaccharides attenuate postburn sepsis via inhibiting negative immunoregulation of CD4 CD25(high) T cells. PLoS One 2011; 6:e19811.
60. Hiraki S, Ono S, Tsujimoto H, et al. Neutralization of interleukin-10 or transforming growth factor-beta decreases the percentages of CD4 CD25 Foxp3 regulatory T cells in septic mice, thereby leading to an improved survival. Surgery 2012; 151:313-322.
61. Hotchkiss RS, Coopersmith CM, Karl IE. Prevention of lymphocyte apoptosis-A potential treatment of sepsis? Clin Infect Dis 2005; 41(Suppl 7):S465-S469.
62. Oberholzer C, Oberholzer A, Bahjat FR, et al. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc Natl Acad Sci USA 2001; 98:11503-11508.
63. Iwata A, Stevenson VM, Minard A, et al. Over-expression of Bcl-2 provides protection in septic mice by a trans effect. J Immunol 2003; 171:3136-3141.
64. Hotchkiss RS, Swanson PE, Knudson CM, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999; 162:4148-4156.
65. Chung CS, Xu YX, Wang W, et al. Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis? Arch Surg 1998; 133:1213-1220.
66. Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: A critical role of the lymphocyte. Nat Immunol 2000; 1:496-501.
67. Sarkar A, Hall MW, Exline M, et al. Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am J Respir Crit Care Med 2006; 174:1003-1010.
68. Exline MC, Justiniano S, Hollyfield JL, et al. Microvesicular caspase-1 mediates lymphocyte apoptosis in sepsis. PLoS One 2014; 9:e90968.
69. Methot N, Huang J, Coulombe N, et al. Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics. J Exp Med 2004; 199:199-207.
70. Oliva-Martin MJ, Sanchez-Abarca LI, Rodhe J, et al. Caspase-8 inhibition represses initial human monocyte activation in septic shock model. Oncotarget 2016; 7:37456-37470.
71. Wang FY, Fang B, Qiang XH, et al. The efficacy and immunomodulatory effects of ulinastatin and thymosin alpha1 for sepsis: A systematic review and meta-Analysis. Biomed Res Int 2016; 2016:9508493.
72. Hasan S, Mosier MJ, Conrad P, et al. Terminal maturation of orthochromatic erythroblasts is impaired in burn patients. J Burn Care Res 2017. [Epub ahead of print]
73. Hasan S, Johnson NB, Mosier MJ, et al. Myelo-erythroid commitment after burn injury is under beta-Adrenergic control via MafB regulation. Am J Physiol Cell Physiol 2017; 312:C286-C301.
74. Johnson NB, Posluszny JA, He LK, et al. Perturbed MafB/GATA1 axis after burn trauma bares the potential mechanism for immune suppression and anemia of critical illness. J Leukoc Biol 2016; 100:725-736.
75. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507.
76. Charles A, Shaikh AA, Walters M, et al. Blood transfusion is an independent predictor of mortality after blunt trauma. Am Surg 2007; 73:1-5.
77. Malone DL, Dunne J, Tracy JK, et al. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. J Trauma 2003; 54: 898-905.
78. Finch C. Regulators of iron balance in humans. Blood 1994; 84: 1697-1702.
79. Kim A, Nemeth E. New insights into iron regulation and erythropoiesis. Curr Opin Hematol 2015; 22:199-205.
80. Rivera S, Liu L, Nemeth E, et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-Associated anemia. Blood 2005; 105: 1797-1802.
81. Roy CN, Mak HH, Akpan I, et al. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007; 109: 4038-4044.
82. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98:8780-8785.
83. Viatte L, Lesbordes-Brion JC, Lou DQ, et al. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood 2005; 105: 4861-4864.
84. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271-1276.
85. Rodriguez R, Jung CL, Gabayan V, et al. Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect Immun 2014; 82:745-752.
86. Armitage AE, Eddowes LA, Gileadi U, et al. Hepcidin regulation by innate immune and infectious stimuli. Blood 2011; 118:4129-4139.
87. van Eijk LT, John AS, Schwoebel F, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood 2014; 124:2643-2646.
88. Opelz G, Vanrenterghem Y, Kirste G, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997; 63:964-967.
89. Offner PJ, Moore EE, Biffl WL, et al. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg 2002; 137:711-716.
90. Vamvakas EC, Moore SB. Blood transfusion and postoperative septic complications. Transfusion 1994; 34:714-727.
91. Paulson RF, Shi L, Wu DC. Stress erythropoiesis: new signals and new stress progenitor cells. Curr Opin Hematol 2011; 18:139-145.
92. Lenox LE, Perry JM, Paulson RF. BMP4 and Madh5 regulate the erythroid response to acute anemia. Blood 2005; 105:2741-2748.
93. Wu DC, Paulson RF. Hypoxia regulates BMP4 expression in the murine spleen during the recovery from acute anemia. PLoS One 2010; 5:e11303.
94. Murtaugh LC, Chyung JH, Lassar AB. Sonic hedgehog promotes somitic chondrogenesis by altering the cellular response to BMP signaling. Genes Dev 1999; 13:225-237.
95. Lau CI, Outram SV, Saldana JI, et al. Regulation of murine normal and stressinduced erythropoiesis by Desert Hedgehog. Blood 2012; 119: 4741-4751.
96. Agosti V, Karur V, Sathyanarayana P, et al. A KIT juxtamembrane PY567-directed pathway provides nonredundant signals for erythroid progenitor cell development and stress erythropoiesis. Exp Hematol 2009; 37:159-171.
97. Perry JM, Harandi OF, Paulson RF. BMP4, SCF, and hypoxia cooperatively regulate the expansion of murine stress erythroid progenitors. Blood 2007; 109:4494-4502.
98. Alamo IG, Kannan KB, Loftus TJ, et al. Severe trauma and chronic stress activates extramedullary erythropoiesis. J Trauma Acute Care Surg 2017; 83:144-150.
99. Li Y., Zhou T., Wang Y., et al.The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation. Oncogene, 2017, 36 3760-3771
100. Millot S, Andrieu V, Letteron P, et al. Erythropoietin stimulates spleen BMP4-dependent stress erythropoiesis and partially corrects anemia in a mouse model of generalized inflammation. Blood 2010; 116:6072-6081.
101. Hattangadi SM, Wong P, Zhang L, et al. From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood 2011; 118:6258-6268
102. Ghaffari S, Kitidis C, Zhao W, et al. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood 2006; 107:1888-1891.
103. Zhang J, Lodish HF. Endogenous K-ras signaling in erythroid differentiation. Cell Cycle 2007; 6:1970-1973.
104. Petruliene K, Ziginskiene E, Kuzminskis V, et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Medicina (Kaunas) 2017; 53:90-100.
105. Alamo IG, Kannan KB, Smith MA, et al. Characterization of erythropoietin and hepcidin in the regulation of persistent injury-Associated anemia. J Trauma Acute Care Surg 2016; 81:705-712.
106. Bible LE, Pasupuleti LV, Alzate WD, et al. Early propranolol administration to severely injured patients can improve bone marrow dysfunction. J Trauma Acute Care Surg 2014; 77:54-60.
107. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288:2827-2835
108. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebocontrolled trial. Crit Care Med 1999; 27:2346-2350
109. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients .N Engl J Med 2007; 357:965-976.
110. Pieracci FM, Stovall RT, Jaouen B, et al. A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness. Crit Care Med 2014; 42 2048-2057